Crossject

Equities

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:37:09 2024-04-25 am EDT			5-day change	1st Jan Change
2.01 ^EUR	-5.63%		-1.47%	-59.56%

Apr. 03	CROSSJECT : Patience is a virtue… hopefully	AL
Apr. 02	Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Crossject : Biotech showcase Partnering

December 23, 2020 at 04:19 am EST

Our business development team will attend the Biotech Showcase Partnering for meetings with investors and strategic executives, to present Crossject and discuss potential opportunities with ZENEO®.

Attachments

Original document
Permalink

Disclaimer

Crossject SA published this content on 23 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 December 2020 09:18:06 UTC

Latest news about Crossject

CROSSJECT : Patience is a virtue… hopefully	Apr. 03	AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
CROSSJECT : Invest Securities slightly reduces its target	Feb. 28	CF
CROSSJECT : Securing the financing needs	Feb. 28	AL
Crossject: share price falls after convertible bond issue	Feb. 27	CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding	Feb. 25	CI
CROSSJECT : No news is not always good news...	Feb. 08	AL
Crossject: strategy advances, but visibility worries	Feb. 07	CF
CROSSJECT : Marketing initiative in the US	Jan. 06	AL
Crossject: Syneos Health hired for Zepizure in the USA	Jan. 05	CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment	Jan. 05	MT
CROSSJECT : A new distribution agreement in Northern Europe	Jan. 03	AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU	Dec. 22	MT
Crossject: commercial agreement in Northern Europe	Dec. 22	CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe	Dec. 22	CI
CROSSJECT : H1 23: no surprises before the release of the detailed accounts in October	23-09-28	AL
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Crossject: improved ESG rating in the Gaïa ranking	23-09-11	CF
Crossject: manufacturing audits passed	23-09-05	CF
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US	23-09-05	MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication	23-07-20	MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand	23-07-20	CI
Crossject: appointment to the Supervisory Board	23-06-02	CF
CROSSJECT : No real news in the FY22 results.	23-03-27	AL
CROSSJECT : FY22: not much to learn from the release	23-03-23	AL

Chart Crossject

Duration

Period

More charts

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Sector

Medical Equipment, Supplies & Distribution

More about the company